中位无进展生存期为6个月。
共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
在两项研究中，主要功效评估指标是无进展生存期。
In both studies, the primary efficacy endpoint was progression-free survival.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
首要观察终点从总生存期(OS)改为无进展生存期(PFS)。
The primary end point was amended from overall survival (OS) to progression-free survival (PFS).
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
主要指标是总生存期，次要指标包括无进展生存期(PFS)和客观反应率(ORR)。
The primary endpoint was overall survival, and secondary endpoints included PFS and objective response rate (ORR).
主要研究终点为无进展生存（PFS），次级研究终点包括客观有效率、总生存和安全性。
The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety.
在确诊时的转化预示相对较好的预后，5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
术后替莫唑胺化疗组中位无进展生存期较单纯手术组显著延长（P<0.05），其余各组之间差异无统计学意义。
PFS of temozolomide chemotherapy group is higher than that of single operation group(P<0.05), and there were no significant differences of PFS between the other groups.
即使无进展生存期的中位数看起来不相同，风险比是0.6。“因为存在一个重要的患者子集通过一个重要途径受益。”
Even though the median in PFS doesn't look different, the HR is 0.6 "because there is a significant patient subset who benefit in a significant way. ""
阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。
INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
多数的专家认为这得益于“无进展生存”，阿瓦斯丁已经被许多肿瘤学家作为“未贴签”药物用于治疗，足以完全通过审批。
Most scientific experts consider this benefit "progression-free survival," sufficient for full approval, and many oncologists have been using Avastin as an "off-label" drug for this purpose.
他指出，研究结果还表明，患者的一个子集可能表现出更显著的效应。这在无进展生存期（PFS）的结果中能明显地看出来。
The findings also suggest that a subset of patients may be achieving a more significant benefit. This is apparent in the results of PFS, he pointed out.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
应用推荐